What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Black triangle. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet is: Pl 10673/0042.

Panzyga 100 mg/ml solution for infusion

Package leaflet: Information for the user

Panzyga, 100 mg/ml solution for infusion

Human Normal Immunoglobulin (IVIg)

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Panzyga is and what it is used for
2. What you need to know before you use Panzyga
3. How to use Panzyga
4. Possible side effects
5. How to store Panzyga
6. Contents of the pack and other information

1. What Panzyga is and what it is used for

What Panzyga is

Panzyga is a human normal immunoglobulin (IgG) solution (i.e. solution of human antibodies) for intravenous administration (i.e. infusion into a vein). Immunoglobulins are normal constituents of the human blood and support the immune defence of your body. Panzyga contains all IgG which are present in the human blood of healthy people. Adequate doses of Panzyga may restore abnormally low IgG levels to the normal range.

Panzyga has a broad spectrum of antibodies against various infectious agents.

What Panzyga is used for

Panzyga is used for the treatment of children and adults (replacement therapy). There are 4 groups of patients where replacement therapy is used:

  • Patients with inborn deficiency of antibodies (primary immunodeficiency syndromes, such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies)
  • Patients with diseases of the blood that lead to a lack of antibodies and to recurrent infections (Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections)
  • Patients who have low levels of immunoglobulins after the transplantation of stem cells
  • Patients with congenital AIDS who have repeated bacterial infections

Panzyga can be further used in the treatment of inflammatory disorders (immunomodulation). There are 5 groups of patients:

  • In patients with immune thrombocytopenia (ITP), a condition where the platelets get destroyed and are therefore reduced in number, and who have a high risk of bleeding or need to correct the platelet count prior to surgery
  • In patients with Kawasaki disease, a condition that leads to inflammation of various organs
  • In patients with Guillain Barré syndrome, a condition that leads to inflammation of certain parts of the nervous system

2. What you need to know before you use Panzyga

Do NOT use Panzyga:

  • if you are allergic to human normal immunoglobulin or any of the other ingredients contained in Panzyga (listed in section 6).
  • if you have a deficiency of immunoglobulin A (IgA deficiency) and if you have developed antibodies against immunoglobulins of the type IgA.

Warnings and precautions

Talk to your doctor or pharmacist before using Panzyga.

Certain adverse reactions may occur more frequently:

  • in case of high rate of infusion
  • when you receive Panzyga for the first time or, in rare cases, when there has been a long interval since the previous infusion.

In the case of an adverse reaction, your doctor will either reduce the rate of administration or stop the infusion. The treatment of the adverse event required will depend on the nature and severity of the adverse event.

Circumstances and conditions increasing the risk of having side effects

  • If you had kidney problems in the past or if you have certain risk factors like diabetes, overweight, or age over 65, Panzyga should be administered as slow as possible because cases of acute kidney failure have been reported in patients with such risk factors. Tell your doctor, even when any of the above-mentioned circumstances had happened to you in the past.
  • Thromboembolic events such as heart attack, stroke, and obstructions of a deep vein for example in the calves or of a blood vessel in the lung may occur very rarely after administration of Panzyga. These types of events occur more commonly in patients with risk factors, such as obesity, advanced age, high blood pressure, diabetes, previous occurrences of such events, prolonged periods of immobilisations, and intake of certain hormones (e.g. the pill). Ensure a balanced fluid intake; moreover Panzyga should be administered as slow as possible.
  • Allergic reactions are rare, but can induce an anaphylactic shock, even in patients who had tolerated the previous treatments.
  • Strong headaches and neck stiffness may rarely occur several hours to 2 days following Panzyga treatment.
  • Patients with blood group A, B or AB as well as patients with certain inflammatory conditions have a higher risk of red blood cells being destroyed by the administered immunoglobulins (called haemolysis).

Effects on blood tests

Panzyga contains a wide variety of different antibodies, some of which can affect blood tests. If you have a blood test after receiving Panzyga, please inform the person taking your blood or your doctor that you have received the human normal immunoglobulin.

Virus safety

When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:

  • careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded
  • testing of each donation and pools of plasma for signs of virus/infections
  • steps included by the manufacturers in the processing of the blood or plasma that can inactivate or remove viruses.

Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.

The measures taken are considered effective for encapsulated viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus and for the non-encapsulated viruses such as hepatitis A virus and parvovirus B19.

Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.

It is strongly recommended that every time you receive a dose of Panzyga the name and batch number of the product are recorded in order to maintain a record of the batches used.

Children and adolescents

There are no specific or additional warnings or precautions applicable for children and adolescents.

Other medicines and Panzyga

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, or if you have received a vaccination in the last three months.

Panzyga may impair the effect of live attenuated virus vaccines such as

  • measles
  • rubella
  • mumps
  • varicella.

After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor or pharmacist if you can get or continue with Panzyga.

Driving and using machines

The ability to drive and operate machines may be impaired by some adverse reactions associated with Panzyga. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.

Panzyga contains sodium

This medicinal product contains not more than 0.03 mmol (or 0.69 mg) sodium per ml. To be taken into consideration by patients on a controlled sodium diet.

3. How to use Panzyga

Your doctor will decide if you need Panzyga and at what dose. Panzyga is administered as an intravenous infusion (infusion into a vein) by healthcare personnel. The dose and dosage regimen is dependent on the indication and may need to be individualised for each patient.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Use in children and adolescents

The administration of Panzyga in children and adolescents (intravenously) does not differ from the administration in adults.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Contact your doctor as soon as possible if you suffer from any of the serious side effects listed below (all are very rare and may affect up to 1 in 10,000 infusions). In some cases your doctor may need to interrupt treatment and reduce your dose or stop treatment:

  • Swelling of the face, tongue and windpipe that can cause great difficulty in breathing
  • A sudden allergic reaction with shortness of breath, rash, wheezing and drop of blood pressure
  • Stroke that may cause weakness and / or loss of sensation down one side of the body
  • Heart attack causing chest pain
  • Blood clot causing pain and swelling of limbs
  • Blood clot in lung causing chest pain and breathlessness
  • Anaemia causing shortness of breath or looking pale
  • Severe kidney disorder that may cause you to not pass urine
  • Meningitis causing strong headache

If you experience any of the symptoms above, contact your doctor as soon as possible.

The following other side effects have also been reported:

Common side effects (may affect up to 1 in 10 infusions):

Headache, nausea, fever

Uncommon side effects (may affect up to 1 in 100 infusions):

Skin rash, back pain, chest pain, chills, dizziness, feeling tired, cough, vomiting, belly pain, joint pain, muscle pain, infusion site itching, reduced sense of touch or sensation, reduction of red blood cells, reduction of white blood cells, aseptic meningitis, eye itching, fast beating of the heart, increased blood pressure, ear pain, stiffness, feeling cold, changes in blood tests that report on how the liver is working.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Panzyga

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of the month.

Store in a refrigerator (2°C – 8°C). Keep the container in the outer carton in order to protect from light. Do not freeze.

The product may be removed from the refrigerator for a period of 12 months (without exceeding the expiry date) and stored above +8°C and below +25°C. At the end of this period, the product should not be refrigerated again and should be disposed of. The date at which the product was taken out of the refrigerator should be recorded on the outer carton.

Do not use this medicine if you notice that the solution is cloudy, has deposits or is coloured intensively.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Panzyga contains

  • The active substance is human normal immunoglobulin. Panzyga contains 100 mg/ml human protein of which at least 95% is immunoglobulin G (IgG).
  • The other ingredients are glycine and water for injections.

What Panzyga looks like and contents of the pack

Panzyga is a solution for infusion and is available in vials (1 g/10 ml, 2.5 g/25 ml) or bottles (5 g/50 ml, 6 g/60 ml, 10 g/100 ml, 20 g/200 ml, 30 g/300 ml).

Pack sizes:

1 vial (1 g/10 ml; 2.5 g/25 ml)

1 bottle ( 5 g/50 ml; 6 g/60 ml; 10 g/100 ml; 20 g/200 ml; 30 g/300 ml)

3 bottles (10 g/100 ml; 20 g/200 ml)

The solution is clear or slightly opalescent, colourless or slightly yellow.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Octapharma Ltd.
The Zenith Building
26 Spring Gardens
Manchester
M2 1AB
United Kingdom

Manufacturers

Octapharma
72 rue du Maréchal Foch
67380 Lingolsheim
France

Octapharma Pharmazeutika Produktionsges.m.b.H.
Oberlaaer Strasse 235
1100 Vienna
Austria

This medicinal product is authorised in the member states of the EEA under the following names:

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom: Panzyga®

Italy: Globiga®

This leaflet was last approved in 07/2018.